Increased C-reactive protein levels in the polycystic ovary syndrome: A marker of cardiovascular disease
Increased C-reactive protein levels in the polycystic ovary syndrome: A marker of cardiovascular disease
复制标题
DOI：
10.1210/jc.2003-031096
复制
发表时间：
2004-05-01
影响因子：
5.8
通讯作者：
Blumenfeld, Z
中科院分区：
文献类型：
--
作者：
Boulman, N;Levy, Y;Blumenfeld, Z
多囊卵巢综合征（PCOS）是最常见的生殖异常之一，具有代谢性心血管综合征的某些特征。因此，PCOS患者可能是早发性心血管疾病（CVD）和/或糖尿病高风险女性的最大群体。C反应蛋白（CRP）是未来CVD和/或卒中的一个强有力的独立预测因子。只有一个小的已发表的研究寻找这样的关联（17例PCOS患者与15例对照）。本研究的目的是比较PCOS患者和对照组的CRP水平和其他CVD危险因素。对116例PCOS患者和94例体重指数匹配的正常对照者进行了CRP测定。PCOS组CRP水平高于5 mg/L者占36.8%，对照组CRP水平高于5 mg/L者仅占9.6%（P < 0.001）。PCOS组的平均+/- SD为5.46 +/- 7.0，对照组为2.04 +/- 1.9 mg/L（P < 0.001）。体重指数、白色血细胞计数、TSH、血糖、胆固醇和同型半胱氨酸水平在两组之间没有显著差异。PCOS患者CRP水平升高，可能是这些患者早期心血管风险的标志物。高CRP水平可以解释为什么一些PCOS女性可能会增加早发性CVD的风险。因此，针对降低CVD危险因素的治疗方案是否应该对那些CRP水平升高的PCOS妇女更积极，有待进一步的临床经验。
The polycystic ovary syndrome ( PCOS), one of the most common reproductive abnormalities, shares some components of the metabolic cardiovascular syndrome. Therefore, PCOS patients may represent the largest group of women at high risk for the development of early-onset cardiovascular disease (CVD) and/or diabetes. C-reactive protein (CRP) is a strong independent predictor of future CVD and/or stroke. Only one small published study has looked for such an association (17 PCOS patients vs. 15 controls). The objective of this study was to compare the levels of CRP and other risk factors of CVD in a large group of PCOS patients and controls. CRP measurements were undertaken in 116 PCOS patients and 94 body mass index-matched controls with regular menstrual cycles. Whereas 36.8% of the PCOS patients had CRP levels above 5 mg/liter, only 9.6% of the controls exhibited high CRP levels (P < 0.001). The mean +/- SD was 5.46 +/- 7.0 in the PCOS group vs. 2.04 +/- 1.9 mg/liter in the control (P < 0.001). The body mass index, white blood cell count, TSH, glucose, cholesterol, and homocysteine levels were not significantly different between the two groups. CRP levels are elevated in patients with PCOS and may be a marker of early cardiovascular risk in these patients. High CRP levels may explain why some PCOS women may possibly be at an increased risk for the development of early-onset CVD. Consequently, whether treatment regimens directed toward lowering CVD risk factors should be more aggressive for those PCOS women with increased CRP levels, awaits further clinical experience.